TWiV 984: Clinical update with Dr. Daniel Griffin
In his weekly clinical update Dr. Griffin discusses the political polarization of COVID-19 treatments among physicians and laypeople in the United States, seven alternatives to evidence-based medicine, Malawi's cholera death toll crosses 1,300 in its deadliest outbreak on record, impact of coronavirus infections on pediatric patients at a tertiary pediatric hospital, maternal mRNA COVID-19 vaccination during pregnancy and delta or omicron infection or hospital admission in infants, yes masks reduce the risk of spreading infection, despite a review saying they don't, COVID-19 and airborne transmission: science rejected, lives lost. can society do better, what were the historical reasons for the resistance to recognizing airborne transmission during the COVID-19 pandemic, a randomized trial comparing Omicron-containing boosters with the original COVID-19 vaccine mRNA-1273, SARS-CoV-2 neutralizing antibodies after bivalent vs. monovalent booster, the impacts of SARS-CoV-2 vaccine dose separation and targeting on the COVID-19 epidemic in England, intra-host evolution provides for the continuous emergence of SARS-CoV-2 variants, real-world use of Nirmatrelvir–Ritonavir in outpatients with COVID-19 during the era of Omicron variants including BA.4 and BA.5 in Colorado, viral burden rebound in hospitalized patients with COVID-19 receiving oral antivirals in Hong Kong, and guidance on the use of convalescent plasma to treat immunocompromised patients with COVID-19.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- The political polarization of COVID-19 treatments in the United States (PNAS)
- Seven alternatives to evidence-based medicine (BMJ)
- Malawi's cholera death toll crosses 1,300 (CBC)
- Impact of coronavirus infections on pediatric patients (JHI)
- Maternal mRNA COVID-19 vaccination during pregnancy (BMJ)
- Yes, masks reduce the risk of spreading COVID (TVO)
- COVID-19 and airborne transmission (IDSA)
- What were the reasons for resistance to recognizing airborne transmission (IJIE)
- Comparing Omicron-containing boosters with COVID-19 vaccine mRNA-1273 (medRxiv)
- SARS-CoV-2 neutralizing antibodies after bivalent vs. monovalent booster (bioRxiv)
- The impact of SARS-CoV-2 vaccine dose separation and targeting (Nature)
- Intra-host evolution provides for the emergence of SARS-CoV-2 variants (ASM)
- Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 (The Lancet)
- Viral rebound in hospitalized patients with COVID-19 receiving oral antivirals (The Lancet)
- Guidance on the use of convalescent plasma to treat immunocompromised patients with COVID-19 (CID)
- Contribute to our ASTMH fundraiser at PWB
- Dr. Griffin's treatment guide (pdf)
- Letters read on TWiV 984
- Don't crush Paxlovid (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv
More description
In his weekly clinical update Dr. Griffin discusses the political polarization of COVID-19 treatments among physicians and laypeople in the United States, seven alternatives to evidence-based medicine, Malawi's cholera death toll crosses 1,300 in its deadliest outbreak on record, impact of coronavirus infections on pediatric patients at a tertiary pediatric hospital, maternal mRNA COVID-19 vaccination during pregnancy and delta or omicron infection or hospital admission in infants, yes masks reduce the risk of spreading infection, despite a review saying they don't, COVID-19 and airborne transmission: science rejected, lives lost. can society do better, what were the historical reasons for the resistance to recognizing airborne transmission during the COVID-19 pandemic, a randomized trial comparing Omicron-containing boosters with the original COVID-19 vaccine mRNA-1273, SARS-CoV-2 neutralizing antibodies after bivalent vs. monovalent booster, the impacts of SARS-CoV-2 vaccine dose separation and targeting on the COVID-19 epidemic in England, intra-host evolution provides for the continuous emergence of SARS-CoV-2 variants, real-world use of Nirmatrelvir–Ritonavir in outpatients with COVID-19 during the era of Omicron variants including BA.4 and BA.5 in Colorado, viral burden rebound in hospitalized patients with COVID-19 receiving oral antivirals in Hong Kong, and guidance on the use of convalescent plasma to treat immunocompromised patients with COVID-19.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- The political polarization of COVID-19 treatments in the United States (PNAS)
- Seven alternatives to evidence-based medicine (BMJ)
- Malawi's cholera death toll crosses 1,300 (CBC)
- Impact of coronavirus infections on pediatric patients (JHI)
- Maternal mRNA COVID-19 vaccination during pregnancy (BMJ)
- Yes, masks reduce the risk of spreading COVID (TVO)
- COVID-19 and airborne transmission (IDSA)
- What were the reasons for resistance to recognizing airborne transmission (IJIE)
- Comparing Omicron-containing boosters with COVID-19 vaccine mRNA-1273 (medRxiv)
- SARS-CoV-2 neutralizing antibodies after bivalent vs. monovalent booster (bioRxiv)
- The impact of SARS-CoV-2 vaccine dose separation and targeting (Nature)
- Intra-host evolution provides for the emergence of SARS-CoV-2 variants (ASM)
- Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 (The Lancet)
- Viral rebound in hospitalized patients with COVID-19 receiving oral antivirals (The Lancet)
- Guidance on the use of convalescent plasma to treat immunocompromised patients with COVID-19 (CID)
- Contribute to our ASTMH fundraiser at PWB
- Dr. Griffin's treatment guide (pdf)
- Letters read on TWiV 984
- Don't crush Paxlovid (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv
Listen elsewhere
Available Results
Generated results are saved to your library for reuse and search.